Literature DB >> 33778670

Abbreviated Gadoxetic Acid-enhanced MRI with Second-Shot Arterial Phase Imaging for Liver Metastasis Evaluation.

Jeong Woo Kim1, Chang Hee Lee1, Yang Shin Park1, Jongmee Lee1, Kyeong Ah Kim1.   

Abstract

Purpose: To evaluate the feasibility of an abbreviated gadoxetic acid-enhanced MRI protocol including second-shot arterial phase (SSAP) imaging for liver metastasis evaluation. Materials and
Methods: For this retrospective study, a total of 197 patients with cancer (117 men and 80 women; mean age, 62.9 years) were included who underwent gadoxetic acid-enhanced MRI performed by using a modified injection protocol for liver metastasis evaluation from July to August 2017. The modified injection protocol included routine dynamic imaging after a first injection of 6 mL and SSAP imaging after a second injection of 4 mL. Image set 1 was obtained with the full original protocol. Image set 2 consisted of T2-weighted, diffusion-weighted, hepatobiliary phase, and SSAP images (the simulated abbreviated protocol). Acquisition time was measured in each image set. The diagnostic performance of each image set was compared by using a jackknife alternative free-response receiver operating characteristic analysis. Image quality evaluation and visual assessment of vascularity were performed on the original arterial phase images, the SSAP images, and their subtraction images.
Results: The acquisition time was significantly shorter in image set 2 than in image set 1 (18.6 vs 6.2 minutes, P <.0001). The reader-averaged figure-of-merit was not significantly different between image sets 1 and 2 (P = .197). The mean motion artifact score was significantly lower for the SSAP images than for the original arterial phase images (P <.001). All hypervascular metastases (n = 72) showed hyperintensity on the SSAP and/or the second subtraction images.
Conclusion: An abbreviated MRI protocol including SSAP is feasible for liver metastasis evaluation, providing faster image acquisition while preserving diagnostic performance, image quality, and visual vascularity.Keywords: Abdomen/GI, Comparative Studies, Liver, MR-Imaging, Metastases© RSNA, 2019Supplemental material is available for this article. 2019 by the Radiological Society of North America, Inc.

Entities:  

Year:  2019        PMID: 33778670      PMCID: PMC7983790          DOI: 10.1148/rycan.2019190006

Source DB:  PubMed          Journal:  Radiol Imaging Cancer        ISSN: 2638-616X


  30 in total

1.  Second shot arterial phase to overcome degraded hepatic arterial phase in liver MR imaging.

Authors:  Yang Shin Park; Jongmee Lee; Jeong Woo Kim; Cheol Min Park; Chang Hee Lee
Journal:  Eur Radiol       Date:  2018-12-14       Impact factor: 5.315

2.  Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine.

Authors:  Matthew S Davenport; Elaine M Caoili; Ravi K Kaza; Hero K Hussain
Journal:  Radiology       Date:  2014-03-08       Impact factor: 11.105

3.  Trends in long-term survival following liver resection for hepatic colorectal metastases.

Authors:  Michael A Choti; James V Sitzmann; Marcelo F Tiburi; Wuthi Sumetchotimetha; Ram Rangsin; Richard D Schulick; Keith D Lillemoe; Charles J Yeo; John L Cameron
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

4.  Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis.

Authors:  Skye C Mayo; Mechteld C de Jong; Carlo Pulitano; Brian M Clary; Srinevas K Reddy; T Clark Gamblin; Scott A Celinksi; David A Kooby; Charles A Staley; Jayme B Stokes; Carrie K Chu; Alessandro Ferrero; Richard D Schulick; Michael A Choti; Giles Mentha; Jennifer Strub; Todd W Bauer; Reid B Adams; Luca Aldrighetti; Lorenzo Capussotti; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2010-06-29       Impact factor: 5.344

5.  Subtraction Images of Gadoxetic Acid-Enhanced MRI: Effect on the Diagnostic Performance for Focal Hepatic Lesions in Patients at Risk for Hepatocellular Carcinoma.

Authors:  Sang Hyun Choi; So Yeon Kim; Seung Soo Lee; Ju Hyun Shim; Jae Ho Byun; Seunghee Baek; Moon-Gyu Lee
Journal:  AJR Am J Roentgenol       Date:  2017-06-13       Impact factor: 3.959

6.  Does hypervascularity of liver metastases as detected on MRI predict disease progression in breast cancer patients?

Authors:  Larissa Braga; Richard C Semelka; Ricardo Pietrobon; Diego Martin; Nestor de Barros; Ulrich Guller
Journal:  AJR Am J Roentgenol       Date:  2004-05       Impact factor: 3.959

7.  The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases.

Authors:  Kent T Sato; Reed A Omary; Christopher Takehana; Saad Ibrahim; Robert J Lewandowski; Robert K Ryu; Riad Salem
Journal:  J Vasc Interv Radiol       Date:  2009-10-20       Impact factor: 3.464

8.  Evaluation of an abbreviated screening MRI protocol for patients at risk for hepatocellular carcinoma.

Authors:  Jennifer Y Lee; Eugene J Huo; Stefanie Weinstein; Charmaine Santos; Alexander Monto; Carlos U Corvera; Judy Yee; Thomas A Hope
Journal:  Abdom Radiol (NY)       Date:  2018-07

9.  Added value of subtraction imaging in detecting arterial enhancement in small (<3 cm) hepatic nodules on dynamic contrast-enhanced MRI in patients at high risk of hepatocellular carcinoma.

Authors:  Chansik An; Mi-Suk Park; Dowhan Kim; Yeo-Eun Kim; Woo-Suk Chung; Hyungjin Rhee; Myeong-Jin Kim; Ki Whang Kim
Journal:  Eur Radiol       Date:  2012-11-09       Impact factor: 5.315

10.  Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases.

Authors:  C J Zech; P Korpraphong; A Huppertz; T Denecke; M J Kim; W Tanomkiat; E Jonas; A Ba-Ssalamah
Journal:  Br J Surg       Date:  2014-03-20       Impact factor: 6.939

View more
  1 in total

Review 1.  [Recent Updates of Abbreviated MRI for Hepatocellular Carcinoma Screening].

Authors:  Jeong Woo Kim; Chang Hee Lee
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-03-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.